AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

Graphical abstract

Highlights
- Lack of TCF1+ CD8 T cells underlies poor response of STK11 mutant NSCLC to anti-PD-1
- Axl inhibition induces type I interferon and expansion of TCF1+ CD8 T cells
- Axl inhibition sensitizes STK11/LKB1 mutant NSCLC to anti-PD-1 therapy
- Preliminary clinical data supports inhibition of Axl and PD-1 in STK11 mutant NSCLC

Authors
Huiyu Li, Zhida Liu, Longchao Liu, ..., Yang-Xin Fu, John D. Minna, Rolf A. Brekken

Correspondence
zhida_liu@saari.org.cn (Z.L.), yang-xin.fu@utsouthwestern.edu (Y.-X.F.), john.minna@utsouthwestern.edu (J.D.M.), rolf.brekken@utsouthwestern.edu (R.A.B.)

In brief
Li et al. provide mechanistic insight into why lung cancers with a common mutation (LKB1/STK11) are largely insensitive to immune therapy. The authors also demonstrate that inhibition of AXL activity in dendritic cells can restore sensitivity to immune therapy in LKB1/STK11 mutant lung cancer.
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

Huiyu Li,1,2 Zhida Liu,3,16,* Longchao Liu,3 Hongyi Zhang,4 Chuanhui Han,3 Luc Girard,1,13 Hyunsil Park,1 Anli Zhang,3 Chunbo Dong,3 Jianfeng Ye,5 Austin Rayford,5,11 Michael Peyton,1 Xiaoguang Li,3 Kimberley Avila,1 Xuezhi Cao,7 Shuiqiang Hu,1 Md Maksudul Alam,3 Esra A. Akbay,3 Luisa M. Solis,2 Carmen Behrens,8 Shania Hernandez-Ruiz,8 Wei Lu,8 Ignacio Wistuba,8 John V. Heymach,9 Michael Chisamore,10 David Micklem,1 Hani Gabra,5 Gro Gausdal,5 James B. Lorens,11 Bo Li,4,12 Yang-Xin Fu,3,12,* John D. Minna,1,2,13,14,15,* and Rolf A. Brekken1,2,6,13,14,17,*

1Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX 75390-8593, USA
2Cancer Biology Graduate Program, UT Southwestern Medical Center, Dallas, TX 75390, USA
3Department of Pathology, UT Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX 75390-9072, USA
4Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA
5BerGenBio ASA, Bergen, Norway
6Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA
7Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
8Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
9Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
10Merck & Co., Inc., Kenilworth, NJ 07033, USA
11Department of Biomedicine, Centre for Cancer Biomarkers, Norwegian Centre of Excellence, University of Bergen, Bergen, Norway
12Department of Immunology, UT Southwestern Medical Center, Dallas, TX 75390, USA
13Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA
14Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA
15Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA
16Present address: Shanxi Academy of Advanced Research and Innovation, 030032 Taiyuan, China
17Lead contact
*Correspondence: zhida_liu@saari.org.cn (Z.L.), yang-xin.fu@utsouthwestern.edu (Y.-X.F.), john.minna@utsouthwestern.edu (J.D.M.), rolf.brekken@utsouthwestern.edu (R.A.B.)
https://doi.org/10.1016/j.xcrm.2022.100554

SUMMARY

Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor patient responses to immune checkpoint blockade (ICB), and introduction of a Stk11/Lkb1 (L) mutation into murine lung adenocarcinomas driven by mutant Kras and Trp53 loss (KP) resulted in an ICB refractory syngeneic KPL tumor. Mechanistically this occurred because KPL mutant NSCLCs lacked TCF1-expressing CD8 T cells, a phenotype recapitulated in human STK11/LKB1 mutant NSCLCs. Systemic inhibition of Axl results in increased type I interferon secretion from dendritic cells that expanded tumor-associated TCF1+PD-1+CD8 T cells, restoring therapeutic response to PD-1 ICB in KPL tumors. This was observed in syngeneic immunocompetent mouse models and in humanized mice bearing STK11/LKB1 mutant NSCLC human tumor xenografts. NSCLC-affected individuals with identified STK11/LKB1 mutations receiving bemcentinib and pembrolizumab demonstrated objective clinical response to combination therapy. We conclude that AXL is a critical targetable driver of immune suppression in STK11/LKB1 mutant NSCLC.

INTRODUCTION

Immune checkpoint blockade (ICB) therapy, especially anti-programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) therapy, has revolutionized non-small cell lung cancer (NSCLC) treatment, with clinical trials showing significantly prolonged survival for responding subjects.1,2 However, ICB-induced clinical and survival benefit is limited to ~20% of NSCLC-affected individuals due to multiple mechanisms of ICB resistance, most of which are unknown.3,4 Mutant KRAS-driven NSCLCs tend to have a higher response rate to PD-1/PD-L1 inhibition compared with KRAS wild-type (WT) NSCLCs.5,6 However, when KRAS is co-mutated with STK11/LKB1 (incidence rate ~11% in lung adenocarcinoma [LUAD]), responses to ICB are usually abrogated.7–11 STK11/LKB1 (L) is a tumor suppressor gene that encodes a master serine threonine kinase involved in cell growth, metabolism,
and polarity by interacting with multiple downstream mediators including AMPK.\textsuperscript{12–14} Mutations in KRAS and STK11/LKB1 (KL) correlate with a more immunosuppressive tumor microenvironment (TME), which may account for the limited response to anti-PD-1/PD-L1 treatment.\textsuperscript{15,16} Therefore, strategies that sensitize KL and L mutant NSCLC to ICB therapy would provide a significant clinical impact.

Stem-like T cell factor 1 (TCF1) (encoded by Tcf7) expressing PD-1\textsuperscript{+} CD8 T cells are a key cell population that respond to PD-1/PD-L1 blockade in the TME.\textsuperscript{17–21} Existence of TCF1\textsuperscript{+}PD1\textsuperscript{+}CD8 T cells allows for the expansion of differentiated TCF1\textsuperscript{+}PD1\textsuperscript{+}CD8 T cells in response to anti-PD-1/PD-L1 therapy, ultimately leading to tumor growth control. However, no pharmacologic agent has been shown to expand TCF1\textsuperscript{+}PD1\textsuperscript{+}CD8 T cells effectively. Furthermore, the status of TCF1\textsuperscript{+}PD1\textsuperscript{+}CD8 T cells in STK11/LKB1 mutated NSCLC tumors has not been investigated.

Although ICB can reverse the exhaustion status of CD8 T cells in tumors, the activation and differentiation of tumor-specific CD8 T cells requires antigen presentation by antigen-presenting cells (APCs). Axl, a receptor tyrosine kinase, is an innate checkpoint regulating APC activation.\textsuperscript{22–24} Activation of Axl on innate immune suppresses type I interferon production, a critical signaling pathway for priming and activating anti-tumor CD8 T cells.\textsuperscript{25,26} Thus, Axl inhibition is an attractive strategy to potentially expand PD-1\textsuperscript{+} tumor-specific T cells and improve ICB efficacy.\textsuperscript{30}

We investigated the immune landscape of mutant KRAS-driven NSCLC with and without STK11/LKB1 mutations and used mouse models of KL NSCLC to determine if Axl inhibition enhances the efficacy of anti-PD-1 therapy. We found that murine NSCLCs with mutant Stk11/Lkb1 lack TCF1\textsuperscript{+}PD1\textsuperscript{+}CD8 T cells and that this deficiency limits response to ICB. We further demonstrate that Axl inhibition facilitates the expansion of TCF1\textsuperscript{+}PD1\textsuperscript{+}CD8 T cells by interrupting Axl function in a subset of APCs. These preclinical observations are being evaluated in a clinical trial testing the benefit of combining bemcentinib, an Axl inhibitor, with the anti-PD-1 antibody pembrolizumab in NSCLC-affected individuals, some of which harbor mutations in STK11/LKB1.

RESULTS

**STK11/LKB1 mutated NSCLC lacks anti-PD-1 treatment-responsive T cells in the TME**

To dissect the immune landscape of STK11/LKB1 mutant NSCLC, we used an isogenic pair of syngeneic murine LUAD cell lines derived from a tumor arising in a mutant Kras/Tp53 knockout genetically engineered mouse model (referred to as “KP” tumor cells). KP expresses WT Stk11/Lkb1, while KPL was CRISPR engineered to also be Stk11/Lkb1 deficient with decreased AMPK alpha activation (Figure S1A). KP and KPL cells form syngeneic tumors with adenocarcinoma histology in C57BL/6J mice (Figure S1B). Subcutaneous KP tumors grew faster than KPL tumors in immunodeficient NSG-SGM3 mice, while KPL grew faster than KP when injected into immune intact C57BL/6J mice (Figures S1C and S1D). Importantly, when KP and KPL cells were injected into Rag1-deficient mice (Rag1 KO), the resulting tumors exhibited similar growth patterns (Figure S1E), suggesting that tumor progression differences caused by loss of Stk1/Lkb1 are mediated by the host adaptive immune system.

Consistent with previous reports in KL-mutated NSCLC human tumors, we found that mouse KPL tumors exhibited poor response to anti-PD-1 therapy and a T cell infiltration pattern similar to clinical STK11/LKB1 mutant individuals reported previously (Figures 1A and S1F).\textsuperscript{11} To assess the effect of Stk11/Lkb1 mutation on the immune landscape of NSCLC, we performed single-cell RNA sequencing (scRNA-seq) on myeloid cells and T cells isolated from KP and KPL syngeneic murine tumors as described.\textsuperscript{31} Well-defined cell clusters were annotated with previous reported functional markers (Figures S2A–S2D). CD8 T cells from KP and KPL tumors were aggregated and clustered (see STAR Methods) into terminal exhausted T cells, central memory T cells, proliferating T cells and inhibitory T cells (Figures 1B and S2E).\textsuperscript{32,33} The percentage of CD8 T cells from KP and KPL tumors in each cluster demonstrates that loss of Stk11/Lkb1 expression in tumor cells is associated with a more suppressive CD8 T cell composition in the TME (Figure 1C). Notably, KPL tumors, in contrast to KP tumors, showed a decreased abundance of Tcf7 expressing CD8 T cells in the KPL TME (Figure 1D). These scRNA-seq observations were confirmed by comparing TCF1\textsuperscript{+}PD1\textsuperscript{+}CD8 T cells in KP and KPL tumors through flow cytometry and immunohistochemistry (Figures 1E, 1F, S3A, and S3B).

We also evaluated central memory-like CD8 T cell infiltration status in LUAD-affected individuals. First, immunohistochemical analysis of 62 of our NSCLC human tumors showed that STK11/ LKB1 mutant tumors exhibited reduced CD8\textsuperscript{+}, Granzyme B\textsuperscript{+} (GzB\textsuperscript{+}), or CD45RO\textsuperscript{+} cells compared with STK11/LKB1 wild type (Figure 1G). Second, we examined The Cancer Genome Atlas (TCGA) database using TIMER deconvolution.\textsuperscript{34} In this data set, TCF7 expression positively correlated with CD8 T cell infiltration (correlation = 0.31, p = 2.43e-12), and CD8 T cell infiltration was reduced significantly in individuals whose tumors harbor a mutation in STK11 (Figure 1H). As TCF1-expressing CD8 T cells exhibit central memory features, lack of these cells in our own and TCGA datasets, indicates the lack of tumor-associated memory T cells in the TME of STK11/LKB1 mutant NSCLC. Collectively, these results suggest the lack of TCF1\textsuperscript{+}CD8 T cells in the TME in STK11/LKB1 mutant NSCLC, which could impact response to anti-PD-1/PD-L1 treatment.

**Bemcentinib-mediated Axl inhibition sensitizes STK11/ LKB1 mutant tumors to anti-PD-1 therapy**

Several studies have implicated that Axl expression by tumor or stromal cells participates in anti-tumor immune response and the TME.\textsuperscript{23,35–39} To investigate whether systemic inhibition of Axl might sensitize KL-mutated tumors to anti-PD-1 treatment, we treated C57BL/6J mice bearing KPL tumors with the selective Axl kinase inhibitor bemcentinib (BGB324) alone, anti-PD-1 alone, or with a combination of anti-PD-1 + BGB324. Although neither treatment alone controlled tumor growth, the combination of BGB324 with anti-PD-1 showed sustained control of tumor progression (Figure 2A). Importantly, BGB324 + anti-PD-1 treatment failed to control the growth of KPL tumors implanted in Rag1 KO mice, demonstrating the therapeutic effect of the
Figure 1. *Stk11/Lkb1* mutant NSCLC lacks anti-PD-1-responsive T cells

(A) C57BL/6J mice (n = 5) were injected with $1 \times 10^6$ KP (left) or KPL (right) tumor cells and treated with anti-PD-1 (10 mg/kg, day 7, 10, 14). Tumor volume was measured every 3 days. ***p < 0.005.

(B) UMAP of sub-clustering tumor-infiltrating CD8 T cells in KP and KPL tumors. T cell clusters are denoted by color.

(C) Composition of CD8 T cells in each cluster from KP and KPL.

(D) The expression level of *Tcf7* in CD8 T cells of KP and KPL detected from scRNA-seq are compared and visualized through feature plot (left) and violin plot (right).

(E) Abundance of TCF1+PD-1+ cells among gated CD8 tumor-infiltrating lymphocytes (TILs) (per mm$^3$ of tumor) on day 14 post tumor cell injection. **p < 0.01.

(F) Visualization and localization of TCF1+ (orange) expressing CD8+ (green) T cells in KP (left) and KPL (right) tumor microenvironment through immunohistochemistry. Scale bar, 100 μm.

(legend continued on next page)
combination is dependent on the adaptive immune system (Figure S4A). By deleting CD4 and CD8 T cells respectively in vivo, we found that the therapeutic efficacy of combination therapy relies on CD8 T cells but not CD4 T cells (Figures S4B and S4C). To assess the TME from each treatment group, we performed flow cytometry with tumors harvested from C57BL/6J mice. BGB324 treatment alone or in combination with anti-PD-1 increased the infiltration of TCF1+PD-1+CD8 T cells significantly (Figures 2B and S4D). We confirmed that the increased infiltration of TCF1+PD-1+CD8 T cells relies on recruitment from spleen instead of pre-infiltrated T cells, and blocking T cell egress abrogated therapeutic efficacy (Figure S4E). We also treated KP tumors with the same treatment regimen and found that combination therapy was not more effective than anti-PD-1 single-agent therapy and did not alter TCF1+PD-1+CD8 T cell tumor infiltration (Figures S4F–S4G).

To dissect the dynamic changes in the KPL TME after treatment, scRNA-seq with paired single-cell TCR sequencing was performed for four pooled samples of the tumor and its TME from each treatment group and annotated with representative markers (Figures S4A–S4D). Sub-clustering of CD8 T cells revealed eight defined sub-populations based on mRNA expression criteria from previous reports (Figures S4A and S4B). Treatment-enriched cells in each cluster within the same treatment group were calculated and compared based on the number of cells observed divided by expected number of cells in each cluster, respectively (Figures 2C and S6C). Treatment of tumors with BGB324 alone significantly enriched CD8 T cells expressing unique TCRs (representing clonally expanded CD8 T cells), with the stem-like T cells and exhausted effector T cells also enriched. Combination therapy showed a trend of enrichment of clonally expanded and exhausted effector CD8 T cells in the TME. TCR lineage tracing to calculate shared TCR clone types between different clusters was performed as described by Guo et al. This analysis demonstrated that the presentation of stem-like T cells correlated the most with clonally expanded T cells, which transit into proliferating and exhausted effector T cells capable of performing direct tumor cell killing (Figures 2D, S6D, and S6E). RNA velocity analysis was performed (see STAR Methods) to predict the future transition status of CD8 T cells in the TME. While BGB324 reversed the inhibitory trend observed in control treatment groups and enhanced the stemness of clonally expanded cells, the combination treatment induced clonally expanded T cells into an activated state (Figure 2E).

We then exploited the use of KPL tumor allografts which we engineered to express ova-albumin peptide (KPL-OVA) to allow us to track OVA antigen-specific T cells in their TME. By staining dissociated OVA-expressing tumors with H-2Kb OVA MHC tetramer (SIINFEKL), we found that Axl inhibition with BGB324 increased the number of OVA antigen-specific CD8 T cells in the TME, and in combination with anti-PD-1 further facilitated T cell infiltration (Figures 2F and S7A). However, BGB324 treatment alone did not activate CD8 T cells directly. A combination of BGB324 with anti-PD-1 was required to transit T cells into effector cells which are capable of mediating tumor cell killing (Figures 2G and S7B).

To further validate the role of TCF1+PD-1+CD8 T cells in sensitizing KPL tumors to anti-PD-1 therapy, we treated Cd8aCreWT Tcf7fl/fl tumor-bearing littermates with combination therapy and found that genetic loss of TCF1 in CD8 cells abolishes therapeutic efficacy (Figure 2H).

These data suggest that pharmacologic inhibition of Axl increases antigen-specific TCF1+PD-1+CD8 T cells in KPL tumors and the expansion of TCF1+PD-1+CD8 T cells are the key population to sensitize KPL tumors to anti-PD-1 therapy.

**Inhibition of Axl in dendritic cells is required for efficacy of anti-PD-1 in STK11/LKB1 mutant tumors**

Since Axl inhibition combined with anti-PD-1 controlled KPL tumor growth and this effect was dependent on immune activation, we used Axl-deficient mice to investigate whether loss of Axl in host cells is sufficient to sensitize KPL tumors to anti-PD-1 treatment, independent from Axl inhibition-mediated tumor cell killing effect (Figures S8B–S8G). Treatment with anti-PD-1 alone was insufficient to control the growth of KPL tumors grown in Axl-deficient mice (Figure 3A). Analysis of the immune landscape of these tumors demonstrated that the loss of Axl in host cells resulted in significantly increased tumor infiltration by TCF1+PD-1+CD8 T cells compared with tumors implanted into Axl WT mice (Figures 3B and S6). Therefore, Axl expression in host cells is critical for the suppression of the expansion of TCF1+PD-1+CD8 T cells in the Stk11/Lkb1 mutant TME.

Through scRNA-seq analysis, we found that Axl was expressed in tumor-associated macrophages and dendritic cells (DCs) and was elevated in tumors that lack Stk11/Lkb1 expression (Figures 3C–3E, S9A, and S9B). To determine which host cell component was critical for Axl inhibition and the therapeutic response to anti-PD-1, macrophages or DCs, were depleted in vivo, respectively, as described. Depletion of macrophages did not impact the therapeutic effect of combined Axl and PD-1 inhibition, suggesting that BGB324-mediated sensitization to anti-PD-1 is independent of macrophages (Figure 3F). By contrast, KPL tumors grown in Batf3-deficient mice, which lack functional CD103+ DCs that are essential for cross-priming, did not respond to combined inhibition of Axl and anti-PD-1 (Figure 3G). These results indicate that inhibiting Axl in DCs is essential for the efficacy of combined Axl and PD-1 inhibition.

**Bemcentinib mediated Axl inhibition induced type I interferon secretion expands TCF1+PD-1+CD8+ T cells**

As inhibition of Axl in DCs is sufficient to sensitize KPL tumors to anti-PD-1 treatment, we then investigated whether TCF1+PD-1+CD8 T cells are regulated by the Axl-IFNAR pathway.23,44
Figure 2. Bemcentinib (BGB324) sensitizes KPL tumors to anti-PD-1

(A) C57BL/6J mice (n = 5) were injected with 1 × 10^6 KPL tumor cells and treated with BGB324 (50 mg/kg, twice daily), anti-PD-1 (10 mg/kg, day 7, 10, 14), or the combination starting on day 7 post tumor cell injection. Control animals were treated with control IgG (10 mg/kg) and vehicle. Tumor volume was measured every 3 days. ****p < 0.001.

(B) Abundance of TCF1+PD-1+ cells among gated CD8+ T cells (per mm^3 of tumor) on day 7 post therapy initiation (day 14 post tumor cell injection). ***p < 0.005; ****p < 0.001.

(C) Treatment enriched distribution of stem, clonal expanded, and exhausted effector CD8+ T cells (see STAR Methods). The ratio of observed cell numbers to random expectation estimated by the Ro/e index through the chi-square test. +++ (Ro/e ≥ 3, p < 0.05) represents highly enriched, ++ (1.2 ≤ Ro/e < 3, p < 0.05) represents enriched, + (0.8 ≤ Ro/e < 1.2, p < 0.05) represents weakly enriched, / (0 < Ro/e < 0.8, p < 0.05) represents not significant or reduced.

(legend continued on next page)
Bone marrow-derived dendritic cells (BMDCs) were co-cultured with dying KPL tumor cells and treated with BGB324 or DMSO. BMDCs treated with BGB324 showed increased secretion of IFN-α (Figure 4A), which was not observed from BMDCs treated with BGB324 and co-cultured with dying KP cells (data not shown). Increased secretion of IFN-α was also observed through co-culturing Axl-deficient BMDCs with dying tumor cells, as well as in tumors lysates from tumors treated with BGB324 (Figures S10A and S10B).

To determine the contribution of type I interferon secretion to BGB324 sensitization of KPL tumors to anti-PD-1 treatment, we inhibited the IFN-αR pharmacologically. Blocking IFN-αR intratumorally diminished response to combined Axl and PD-1 inhibition (Figure 4B) and reduced the infiltration of TCF1+PD-1+CD8+ T cells in the TME (Figures 4C, S10C, and S10D). In addition, blocking the IFN-αR counteracted BGB324 induced TCF1 expression on CD8 T cells in co-cultures of BMDCs with OT-1 CD8 T cells stimulated by OVA (see STAR Methods). This suggests that increased TCF1 expression on CD8 T cells by BGB324 treatment is dependent on the type I interferon-IFN-α axis (Figures 4D and S10E). These results were recapitulated using Axl KO BMDCs (Figures 4E and S10F). Furthermore, type I interferon receptor knockout T cells adoptively transferred to Rag1-deficient mice were unable to respond to BGB324 + anti-PD-1 treatment, while WT T cells adoptively transferred into mice were able to control KPL tumor progression (Figures 4F and S10G). When DCs were stimulated with recombinant IFN-α and co-cultured with CD8 T cells, an increase of TCF1 expression on CD8 T cell was observed both in vitro and in vivo (Figures S11A–S11D). Taken together, these results demonstrate that increased type I IFN secretion as a result of Axl inhibition is critical for inducing TCF1+PD-1+CD8+ T cell expansion in KPL tumors and overcoming resistance to anti-PD-1 therapy.

**Bemcentinib and pembrolizumab combination therapy in STK11/LKB1 mutant NSCLC-affected individuals**

As a part of a multi-arm, ongoing phase II clinical trial of bemcentinib and the anti-PD-1 inhibitor pembrolizumab in previously treated NSCLC (BerGenBio ASA and Merck, Kenilworth NJ, USA, NCT03184571), all individuals with sufficiently large tumor biopsies were subjected to whole-exome sequencing and IHC staining for AXL and PD-L1 expression. Of the 24 chemo-refractory and 30 PD-1 axis inhibitor-refractory individuals sequenced and evaluable for efficacy, three individuals were identified as harboring an STK11/LKB1 mutation. All three of these individuals experienced clinical benefit from the combination therapy and are presented here as case studies for the efficacy of combined AXL and PD-1 inhibition in STK11/LKB1 mutant NSCLC.

The first STK11/LKB1 mutant NSCLC-affected individual is a 79-year-old male who initially achieved a partial response to carboplatin and paclitaxel first-line therapy for 22 months before developing progression of lung and adrenal metastases as well as bone marrow metastasis and enrolling in the study. The individual’s tumor biopsy was negative for PD-L1 expression but showed AXL expression in tumor and immune cells (Figures 6A and 6B). The individual went on to achieve a partial response to the bemcentinib/pembrolizumab combination lasting over 10 months from the start of treatment with a maximum target lesion shrinkage of ~50%, after which the individual demonstrated tumor progression and went off study treatment. At the most-recent follow-up date, the individual was still alive and has survived for over 2 years since starting treatment.

The second STK11/LKB1 mutant NSCLC individual, a 73-year-old male, was treated with first-line pemetrexed and cisplatin and progressed after 8 months. He went onto pembrolizumab monotherapy, where he experienced clinical benefit for 18 months before developing tumor progression with lymph node and chest wall metastases. At the time of screening, the individual’s tumor biopsy was negative for PD-L1 expression and showed strong expression of AXL in tumor-infiltrating immune cells (Figures 6A and 6C). The individual experienced clinical benefit from the bemcentinib/pembrolizumab drug combination, achieving target lesion shrinkage of 50%, after which the individual progressed and died of disease over 2 years since starting treatment.

The third STK11/LKB1 mutant NSCLC-affected individual, a 73-year-old male, was treated with first-line pemetrexed and cisplatin and progressed after 8 months. He went onto pembrolizumab monotherapy, where he experienced clinical benefit for 18 months before developing tumor progression with lymph node and chest wall metastases. At the time of screening, the individual’s tumor biopsy was negative for PD-L1 expression and showed strong expression of AXL in tumor-infiltrating immune cells (Figures 6A and 6C). The individual experienced clinical benefit from the bemcentinib/pembrolizumab drug combination, achieving target lesion shrinkage of 50%, after which the individual progressed and died of disease over 2 years since starting treatment.
stable disease for 3.5 months before receiving a CT scan confirming progressive disease and stopping treatment.

The third STK11/LKB1 mutant NSCLC individual, a 51-year-old male, initially achieved stable disease to single-agent atezolizumab first-line therapy for 4.6 months before developing progression of lung (mediastinal and pleural) and nodal metastases and enrolling in the study. The individual's tumor biopsy was negative for PD-L1 expression and tumor AXL expression but contained sparse AXL+ immune cells (Figures 6A and 6D). The individual experienced clinical benefit from the study drug combination, achieving stable disease for 6.2 months after which the individual developed bone metastases and was taken off the study treatment due to progressive disease.

While these are three anecdotes, we evaluated our tumor tissue microarray consisting of 62 NSCLC-affected individuals annotated for STK11/LKB1 mutation status (55 WT, 7 mutant)
for AXL expression. For all the individuals, we find very limited AXL expression in tumor cells. STK11/LKB1 mutant NSCLC-affected individuals exhibited moderate to strong AXL expression on immune cells, compared with STK11/LKB1 WT individuals, who displayed more heterogeneous AXL expression (Figure 6E). These results suggest that STK11/LKB1 mutant NSCLC individuals express AXL in their TME, which has the potential to serve as a biomarker for evaluating combination therapy with bemcentinib and PD-1 inhibitors.

**DISCUSSION**

In this study, we systematically evaluated response to ICB therapy and the CD8 T cell status in preclinical murine and human models of KL mutant NSCLC. We found that mutation of STK11/LKB1 in tumor cells results in reduced numbers of TCF1+PD-1+CD8 T cells in the TME, which prevents a productive response to anti-PD-1 therapy. We show that inhibition of Axl on DCs in STK11/LKB1 mutant NSCLC tumors increases TCF1+PD-1+CD8 T cells in the TME and confers sensitivity to PD-1 blockade. Our data also indicate that Axl suppresses DC expression of type I IFNs, which are required for expansion of TCF1+CD8 T cells, thus providing mechanistic insight into the paucity of stem-like T cells in STK11/LKB1 mutant tumors and a molecular rationale for the poor response of these tumors to PD-1 inhibition. While this study compared STK11/LKB1 plus KRAS/TP53 mutant LUADs to LUADs that had only KRAS/TPS3 mutations for the effects of Axl targeting on the TME, it is
possible that the beneficial effect of Axl inhibition on ICB will extend beyond STK11/LKB1 mutant NSCLC.

Our scRNA-seq analysis indicates that anti-PD-1 treatment expands all CD8 T cell populations unbiasedly without selective expansion of tumor-associated CD8 T cells specifically. Similar treatment effects of anti-PD-1/PD-L1 were also reported in oral cavity carcinoma models.\textsuperscript{47} On the other hand, Axl inhibition induced TCF1\textsuperscript{+}PD-1\textsuperscript{+}CD8 T cell expansion, an effect not previously seen with other systemic therapies. Previous studies suggest that TCF1\textsuperscript{+}PD-1\textsuperscript{+}CD8 T cells do not secrete IFN-\gamma or exhibit effector T cell characteristics directly.\textsuperscript{20} Thus, while these cells are required for ICB therapy responses, they likely do so by differentiating into effector T cells. Our scRNA-seq analysis with single-cell TCR sequencing lineage tracing suggests that Axl inhibition induces clonal expansion of tumor-specific CD8 T cells from stem cell-like CD8 T cells. However, anti-PD-1 therapy was required for transition into effector T cells (TCF1\textsuperscript{+}PD-1\textsuperscript{+}CD8 T cells) and infiltration into tumor cell nests. Although

Figure 5. Bemcentinib sensitizes human STK11/LKB1 mutant NSCLC tumors in humanized mice
(A) Flow cytometric analysis of Axl expression on A549 and H2122 tumor cells in vitro. MFI is shown.
(B) The effect of BGB324 on cell viability (IC\textsubscript{50}) of A549 and H2122 cells.
(C) AXL immunohistochemistry in A549 and H2122 xenografts grown in humanized mice. A549 scale bar, 250 \(\mu\)m; H2122 scale bar, 100 \(\mu\)m.
(D) Humanization and treatment strategy for tumor-bearing humanized mice.
(E) Humanized NSG-SGM3 mice were injected with 1.5 \(\times\) 10\textsuperscript{6} of A549 cells (n = 5, right flank) and treated with BGB324 (50 mg/kg, twice daily), pembrolizumab (10 mg/kg, day 7, 10, 14), or the combination. Control animals were treated with control IgG (10 mg/kg) and vehicle (Ctrl). Treatment was withdrawn after 20 days. ***p < 0.005.
(F) Humanized NSG-SGM3 mice were injected with 1.5 \(\times\) 10\textsuperscript{6} of H2122 cells (n = 2 for control group and 3 for treatment group, bilateral). Treatment schema is as in (D). Treatment was withdrawn after 20 days. ****p < 0.001.
(G and H) Abundance of TCF1\textsuperscript{+}PD-1\textsuperscript{+} cells among gated CD8\textsuperscript{+} T cells (per mm\textsuperscript{3} of tumor) on day 7 post therapy initiation in A549 (G) and H2122 (H) xenografts. **p < 0.01; ****p < 0.001.
Axl is expressed widely on tumor cells, vasculature and myeloid cells.\textsuperscript{23,48,49} Inhibition of Axl on DCs appears to be the main executor in expanding TCF1+PD-1+CD8 T cells to achieve anti-PD-1-mediated control of STK11/LKB1 mutant NSCLC growth control.

The three NSCLC-affected individuals treated with bemcentinib and pembrolizumab presented here provide encouraging evidence that inhibiting AXL can re-sensitize human STK11/LKB1 mutant NSCLC to ICB. This is especially true considering that tumors from these individuals did not harbor KRAS mutations and had minimal to no PD-L1 expression, making them unlikely candidates to respond to anti-PD-1 monotherapy. Although only a small number of STK11-mutant NSCLCs were detected in this trial, the positive responses of these three individuals support the mechanism presented herein.

In conclusion, we have shown in murine- and human-derived preclinical models that systemic treatment with an Axl inhibitor, bemcentinib, in clinical trials combined with PD-1 checkpoint blockade leads to anti-tumor responses in STK11/LKB1 mutant NSCLCs. Combination treatment is associated with TCF1+CD8 T cell expansion and anti-tumor immune responses. Thus, our data strongly support clinical testing of AXL inhibition in combination with PD-1 checkpoint blockade in STK11/LKB1 mutant NSCLC individuals and potentially in other tumor settings that are refractory to PD-1 blockade and that also exhibit deficits in TCF1+CD8 T cells. In addition, in these trials it will be important to perform correlative studies that demonstrate, in affected individuals, the effects of AXL inhibition on TCF1+CD8 T cells as well as investigate alternative mechanisms of increasing type I IFN induction to expand tumor-associated TCF1+PD-1+CD8 T cells.

Limitations of the study
In this study, we identified that combination of bemcentinib with anti-PD-1 effectively sensitizes STK11/LKB1 mutant NSCLC tumors in syngeneic models, human-derived xenografts implanted into humanized mice, and anecdotal NSCLC-affected individuals. Mechanistically, bemcentinib increased TCF1+CD8 T cells in the
TME by increasing type I interferon production from DCs. Although we confirmed that the increased abundance of TCF1+CD8 T cells is the key mediator of therapeutic response, our study has limitations. We were unable to study Axl expression at the protein level in tumor-associated immune cells, due to the lack of an available Axl antibody to stain cells isolated from tumor tissues. In addition, more human responses are needed to substantiate the efficacy of STK11/LKB1 WT individuals. In addition, there are reports that STK11/LKB1 mutant NSCLC individuals have shown response to single-agent PD-1 blockade. Furthermore, it is unclear how specifically the STK11/LKB1 mutation in these individuals results in a differential response to therapy compared with STK11/LKB1 WT individuals. At the same time, this treatment regimen may benefit other cancer-affected individuals with different oncogenotypes. We anticipate more clinical evidence will emerge as additional studies are performed.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - **Lead contact**
  - **Materials availability**
  - **Data and code availability**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - **Cell line and reagents**
  - **Humanized mice and human cord blood sample processing**
  - **Animal studies**
  - **Clinical trial**
- **METHOD DETAILS**
  - **Cytotoxicity assays**
  - **OVA expressing cell line generation and characterization**
  - In Vitro Co-culture of Bone Marrow Dendritic Cells (BMDCs) and T cells
  - **Immunoblots**
  - **Tumor growth and treatment**
  - **IFN-γ enzyme-linked immunosorbent spot assay (ELISPOT)**
  - **Enzyme-Linked Immunosorbent Assay (ELISA)**
  - **Single cell preparation for flow sorting and flow cytometry**
  - **Library preparation and construction for scRNA-seq and scTCR-seq**
  - **Flow cytometry analysis**
  - **Hematoxylin and Eosin (H&E) staining**
  - **Multiplex immunohistochemistry (IHC)**
  - **Tissue microarrays immunohistochemistry staining**
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - **Statistical analysis**
  - **Flow cytometry cell number normalization**
  - scRNA-seq and scTCR-seq data processing
  - Annotation of cell clusters and data visualization
  - **Differential expression analysis**
  - **Characterization of sample enrichment and state transition of T cell clusters**
  - **RNA velocity analysis**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2022.100554.

ACKNOWLEDGMENTS

This work was supported by a sponsored research agreement from BerGenBio ASA and NIH grants R01 CA243577 and U54 CA210181 (to R.A.B.); NIH SPORE P50 CA070907, U54 CA224065, and CPRIT RP160652 (to J.D.M.); RP150072 and RP180725 (to Y.-X.F.); NIH P30 CA142543 (to R.A.B., J.D.M., and Y.-X.F.), the Elfie Marie Cain Foundation (to R.A.B.), and CPRIT training grant RP210041 (to H.L.). We would like to thank all the individuals who participated in this study. We also thank Zhaoning Wang, Amit Das, Kenneth Huffman, Huacong Huang, Jill Westcott, Long-Shan Li, and Jason Toombs for technical support, instruction, and advice. We thank the technical support of the following laboratory members of the Department of Translational Molecular Pathology Immunoprofiling Laboratory (TMP-IL) at MD Anderson Cancer Center: Mei Jiang, Khaja Khanand, and Jianling Zhou. We also thank the Animal Resources Center, Whole Brain Microscopy Facility, Flow Cytometry Facility, and Tissue Management (P30 CA142543) cores at UT Southwestern for technical assistance and we acknowledge NIH P01 HD087150 for cord blood collection.

AUTHOR CONTRIBUTIONS

Conceptualization, H.L., Z.L., Y.-X.F., J.D.M., and R.A.B.; methodology, H.L., Z.L., H.Z., L.L., C.D., J.Y., X.L., and B.L.; investigation, H.L., Z.L., C.H., H.Z., L.L., G.H., A.Z., C.D., J.Y., A.R., D.G., M.P., X.L., K.A., X.C., L.S., C.B., S.H.-R., L.W., and D.M.; writing, H.L., A.R., D.M., H.G., J.B.L., J.D.M., and R.A.B.; funding acquisition, Y.-X.F., J.D.M., and R.A.; resources, S.H., E.A.A., I.W., M.C., H.G., G.G., J.B.L., B.L., J.D.M., and J.V.H.; supervision, Y.-X.F., J.D.M., and R.A.B.

DECLARATION OF INTERESTS

This work was supported in part by a sponsored research agreement from BerGenBio ASA to R.A.B. A.R., D.M., H.G., and G.G. are current employees of BerGenBio ASA and J.B.L. is a former employee of BerGenBio ASA. M.C. is a current employee of Merck &Co., Inc., Kenilworth, NJ. J.D.M. receives licensing royalties from the NIH and UTSW for distribution of human tumor lines. H.L., Z.L., D.M., J.B.L., J.D.M., and R.A.B. are authors of a patent related to this study. The remaining authors have no competing interests.

Received: May 10, 2021
Revised: October 22, 2021
Accepted: February 8, 2022
Published: March 15, 2022

REFERENCES

1. Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M.J., Powell, S.F., et al. (2018). Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092.
2. Hellmann, M.D., Ciuleanu, T.E., Pluzanski, A., Lee, J.S., Otterson, G.A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salmon, P., et al. (2018). Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104.
3. Carbone, D.P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M.M., Ciulei, T.E., Badin, F., et al. (2017). First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426.

4. Garon, E.B., Rizvi, N.A., Hui, R., Leight, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Agrawal, C., Gubens, M., Horn, L., et al. (2015). Pembroli- zumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028.

5. Jeanson, A., Tomasini, P., Souquet-Bressand, M., Brandonne, N., Bouce- kine, M., Grangeon, M., Chaleat, S., Khobta, N., Milia, J., Mhanna, L., et al. (2018). Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 14, 1095–1101.

6. Kim, J.H., Kim, H.S., and Kim, B.J. (2017). Prognostic value of KRAS muta- tion in advanced non-small-cell lung cancer treated with immune check- point inhibitors: a meta-analysis and review. Oncotarget 8, 48248–48252.

7. Cho, B.C., Lopes, G., Kowalski, D.M., Kasahara, K., Wu, Y.-L., Castro, G., Tuma, H.Z., Criscuolo, R., Aurzua-Garg, D., Loboda, A., et al. (2020). Ab- stract CT084: relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembroli- zumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC. Cancer Res. 80, CT084.

8. Koivunen, J.P., Kim, J., Lee, J., Rogers, A.M., Park, J.O., Zhao, X., Naoki, K., Okamoto, I., Nakagawa, K., Yeap, B.Y., et al. (2008). Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Cauca- sian but not Asian lung cancer patients. Br. J. Cancer 99, 245–252.

9. Shire, N.J., Klein, A.B., Golozar, A., Collins, J.M., Fraeman, K.H., Nord- strom, B.L., McEwen, R., Hembrough, T., and Rizvi, N.A. (2020). STK11 (LKB1) mutations in metastatic NSCLC: prognostic value in the real world. PLoS One 15, e0238358.

10. Skoulidis, F., Arbour, K.C., Hellmann, M.D., Balmanoukian, A.S., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2017). Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417–421.

11. Miller, B.C., Sen, D.R., Al Aboys, R., Bi, K., Vikrud, Y.V., LaFleur, M.W., Yates, K.B., Lako, A., Felt, K., Naoki, G.S., et al. (2019). Subsets of ex- hausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336.

12. Siddiqui, I., Schaebelke, K., Chennupati, V., Fuertes Marraco, S.A., Cal-.deron-Copete, S., Pais Ferreira, D., Carmona, S.J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019). Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccin- ation and checkpoint blockade immunotherapy. Immunity 50, 195–211, e1110.

13. Shackelford, D.B., and Shaw, R.J. (2009). The LKB1-AMPK pathway: repression effects of LKB1 in NSCLC. Cancer Discov. 9, 246–255.

14. Rothlin, C.V., Ghosh, S., Sumita, E.I., Oldstone, M.B., and Lemke, G. (2007). TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124–1136.

15. Varmum, B.C., Young, C., Elliott, G., Garcia, A., Bartley, T.D., Fridell, Y.W., Hunt, R.W., Trail, G., Clogston, C., Toso, R.J., et al. (1995). Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373, 623–626.

16. Chen, J., Yang, Y.F., Yang, Y., Zou, P., Chen, J., He, Y., Shi, S.L., Cui, Y.R., Bai, R., Liang, Y.J., et al. (2018). AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling. Nat. Microbiol. 3, 302–309.

17. Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Archambault, J.M., Lee, H., Arthur, C.D., White, J.M., Kalinke, U., et al. (2011). Type I interferon is selectively required by dendritic cells for im- mune rejection of tumors. J. Exp. Med. 208, 1908–2003.

18. Fuertes, M.B., Woo, S.R., Burnett, B., Fu, Y.X., and Gajewski, T.F. (2013). Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34, 67–73.

19. Szczerba, S., Fraone, T., Mussio, T., Cappello, P., Rossi, S., Pierobon, D., Orinska, P., Zaus, R., Buffone-Paus, S., and Giovarelli, M. (2009). Survival and migration of human dendritic cells are regulated by an IFN-alpha-b- inducible Axl/Gas6 pathway. J. Immunol. 183, 3004–3013.

20. Seitz, H.M., Camenisch, T.D., Lemke, G., Ehr, P.H., and Matsushima, G.K. (2007). Macrophages and dendritic cells use different Axl/Mertk/ Tyro3 receptors in clearance of apoptotic cells. J. Immunol. 178, 5635–5642.

21. Guo, Z., Li, Y., Zhang, D., and Ma, J. (2017). Axl inhibition induces the anti- tumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models. Oncotarget 8, 89761–89774.

22. Zhou, T., Damsky, W., Weizman, O.E., McGeeary, M.K., Hartmann, K.P., Rosen, C.E., Fischer, S., Jackson, R., Flavell, R.A., Wang, J., et al. (2020). IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609–614.

23. Guo, X., Zhang, Y., Zheng, L., Zheng, C., Song, J., Zhang, Q., Kang, B., Liu, Z., Jin, L., Xing, R., et al. (2018). Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978–986.

24. Luoma, A.M., Suo, S., Williams, H.L., Sharova, T., Sullivan, K., Manos, M., Bowling, P., Hodi, F.S., Rahma, O., Sullivan, R.J., et al. (2020). Molecular
pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655–671 e622.
34. Li, B., Liu, J.S., and Liu, X.S. (2017). Revisit linear regression-based deconvolution methods for tumor gene expression data. Genome Biol. 18, 127.
35. Aguilera, T.A., Rafat, M., Castellini, L., Shehade, H., Kariolis, M.S., Hui, A.B., Stehr, H., von Eyben, R., Jiang, D., Ellis, L.G., et al. (2016). Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat. Commun. 7, 13898.
36. Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.L., Hui, E.M., Lotsberg, M.L., Wnuk-Lipinska, K., Terry, S., Tan, T.Z., Lu, N., Trachsel, M.
# STAR METHODS

## KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies** | | |
| InVivoMab anti-mouse PD-1 (RMP1-14) | BioXCell | Cat# BE0146; RRID: AB_10949053 |
| InVivoMab rat IgG2a isotype control (2A3) | BioXCell | Cat# BE0089; RRID: AB_11007769 |
| InVivoMab anti-human PD-1 (J110) | BioXCell | Cat# BE0193; RRID: AB_109850168 |
| InVivoMab mouse IgG1 isotype control (MOPC-21) | BioXCell | Cat# BE0083; RRID: AB_1107784 |
| InVivoMab anti-mouse IFNAR-1 (MAR1-5A3) | BioXCell | Cat# BE0241; RRID: AB_2687723 |
| anti-PD-1 (Pembrolizumab) | N/A | |
| Anti-mCD45 (Flow cytometry, 30-F11) | BioLegend | Cat# 103126; RRID: AB_493535 |
| Anti-mCD3 (Flow cytometry, 145-2C11) | BD Bioscience | Cat# 564379; RRID: AB_2738780 |
| Anti-mCD4 (Flow cytometry, GK1.5) | BioLegend | Cat# 100413; RRID: AB_312698 |
| Anti-mCD8a (Flow cytometry, 53-6.7) | BioLegend | Cat# 100730; RRID: AB_493703 |
| Anti-mCD8b (Flow cytometry, YTS156.7.7) | BioLegend | Cat# 126616; RRID: AB_2562777 |
| Anti-mPD-1 (Flow cytometry, 29F.1A12) | BioLegend | Cat# 135224; RRID: AB_2563523 |
| Anti-mKi-67 (Flow cytometry, 16A8) | BioLegend | Cat# 652404; RRID: AB_2562664 |
| OVA-257-264 (SIINFEKL) peptide bound to H-2Kb Monoclonal Antibody (Flow cytometry, 25-D1.16) | eBioscience | Cat# 17-5743-82; RRID: AB_1311286 |
| Anti-h/Mtcf1/7 (Flow cytometry, C63D9) | Cell Signaling Technologies | Cat# 6444; RRID: AB_2797627 |
| Biotin anti-mouse CD45 Antibody (30-F11) | BioLegend | Cat# 101304; RRID: AB_312969 |
| Rabbit (DA1E) mAb IgG XP® Isotype Control | Cell Signaling Technologies | Cat# 2975; RRID: AB_10699151 |
| Anti-hCD45 (Flow cytometry, HI30) | BioLegend | Cat# 304021; RRID: AB_493654 |
| Anti-hCD3 (Flow cytometry, HIT3a) | BioLegend | Cat# 300327; RRID: AB_1575010 |
| Fixable Viability Dye eFluor™ 506 | Thermo Fisher | Cat# 65-0866-18 |
| iTag Tetramer/PE – H-2 Kb OVA (SIINFEKL) | MBL | Cat# TB-5001-1 |
| Anti-FcγRIIIa receptor (clone 2.4G2) | BD Biosciences | Cat# 553141, RRID: AB_394666 |
| TCF1/TCF7 (C63D9) Rabbit mAb | Cell Signaling Technologies | Cat# 2203; RRID: AB_2199302 |
| CD8α (D4W2Z) XP® Rabbit mAb | Cell Signaling Technologies | Cat# 98941; RRID: AB_2756376 |
| LKB1 (D60C5) Rabbit mAb | Cell Signaling Technologies | Cat# 3047; RRID: AB_2198327 |
| AXL (C89E7) Rabbit mAb | Cell Signaling Technologies | Cat# 8661; RRID: AB_11217435 |
| GAPDH (D16H11) Rabbit mAb | Cell Signaling Technologies | Cat# 5174; RRID: AB_10622025 |
| Anti-rabbit IgG, HRP-linked Antibody | Cell Signaling Technologies | Cat# 7074; RRID: AB_2099233 |
| **Chemicals, peptides, and recombinant proteins** | | |
| TMB Solution (1X) | eBioscience | Cat# 00-4201-56 |
| Sulfadiazine/ Trimethoprim (Aurora Pharmaceutical LLC) | UTSW-Veterinary Drug Services | Cat# 302 |
| GE Healthcare Ficoll-Paque™ Premium | Cytiva | Cat# 17544203 |
| Animal free Collagenase, type A | Sigma | Cat# SCR136 |
| DNAse I | Roche | Cat# 11284932001 |
| Recombinant murine GM-CSF | Peprotech | Cat# 315-03 |
| Recombinant murine IFN-γ | Peprotech | Cat# 210-10 |
| Recombinant human IL-4 | Peprotech | Cat# 400-04 |
| Recombinant human GM-CSF | Peprotech | Cat# 300-03 |
| Recombinant human TNFα | Peprotech | Cat# 300-01A |
| Clophsome®-A-Clodronate Liposomes (Anionic) | FormuMax Scientific | Cat# F70101C-A |
| OVA-257-264 (SIINFEKL) | InvivoGen | Cat# vac-sin |
| Human Papillomavirus (HPV) E7 protein (49-57) | GenScript | Cat# RP20249 |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Ovalbumin           | Sigma-Aldrich | Cat# A2512 |
| pCpGfree-OVA        | InvivoGen | Cat# pcpgf-ova |
| Bovine serum albumin (BSA) | Jackson Immuno Research | Cat# 001-000-173 |
| Normal Goat Serum Blocking Solution, 2.5% | Vector Laboratories | Cat# S-1012-50 |
| Eosin Phloxine Alcoholic Working Solution | Poly Scientific | Cat# s176 |
| Harris Modified Method Hematoxylin Stains | Fisher Chemical | Cat# SH26500D |

Critical commercial assays

| Assay                        | Source              | Identifier |
|-----------------------------|---------------------|------------|
| CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS) | Promega | Cat# G3582 |
| OpalTM 520 Reagent Pack     | PerkinElmer         | Cat# FP1487001KT |
| OpalTM 570 Reagent Pack     | PerkinElmer         | Cat# FP1488001KT |
| ProLong™ Gold Antifade Mountant with DAPI | Invitrogen | Cat# P36931 |
| Chromium i7 Multiplex Kit, 96 rxns | 10x Genomics | Cat# PN-120262 |
| BD Mouse IFN-γ ELISPOT Sets | BD Biosciences      | Cat# 551083 |
| VeriKine-HS Mouse IFN Beta ELISA Kit | PBL Assay Science | Cat# 42410 |
| VeriKine Human IFN Beta ELISA Kit | PBL Assay Science | Cat# 414101 |
| True-Nuclear™ Transcription Factor Buffer Set | BioLegend | Cat# 424401 |
| EasySep™ Mouse CD8+ T Cell Isolation Kit | STEMCELL Technologies | Cat# 19853 |
| EasySep™ Human CD34 Positive Selection Kit II | STEMCELL Technologies | Cat# 18780 |
| EasySep™ Mouse Steptavidin RapidSpheres™ Isolation Kit | STEMCELL Technologies | Cat# 19860 |
| Clarity Max Western ECL Substrate | Bio-Rad | Cat# 1705062 |
| ImmPRESS® HRP Horse Anti-Rabbit IgG Polymer Detection Kit | Vector Laboratories | Cat# MP-7401 |
| e-Myc0 PCR Detection Kits | Bulldog Bio | Cat# 25233 |

Deposited data

- Single cell RNA-seq data and TCR sequencing data: This manuscript, GEO: GSE194166
- Code for single cell RNA-seq analysis: This manuscript, https://doi.org/10.5281/zenodo.5975533

Experimental Models: Cell Lines

| Cell Line | Description | Catalog Number |
|-----------|-------------|----------------|
| KP        | Esra Akbay  | N/A            |
| KPL       | Esra Akbay  | N/A            |
| A549 (Male, Adenocarcinoma, NSCLC) | ATCC | CRL-185 |
| H2122 (Female, Adenocarcinoma, NSCLC) | John Minna and Adi Gazdar | RRID: CVCL_1531 |
| Lenti-X 293T (Female, Kidney) | Takara | Cat# 632180 |

Experimental models: Organisms/strains

| Organism | Description | Catalog Number |
|----------|-------------|----------------|
| C57BL/6/J | UTSW breeding core | Cat# 000664 |
| C57BL/6 (MPF) | Taconic Biosciences | Cat# B6N|
| B6.129S7-Rag1tm1Mom/J mice | Jackson Laboratory | Cat# 002216 |
| NSG-SGM3 mice | Jackson Laboratory | Cat# 013062 |
| B6.129(C)-Baf3tm1Knm/J mice | Jackson Laboratory | Cat# 013755 |
| C57BL/6-Tg(TcraTcrb)1100Mjb/J mice | Jackson Laboratory | Cat# 003831 |

Software and algorithms

| Software | Provider | Website |
|----------|----------|---------|
| GraphPad Prism 9.0.0 | GraphPad Software, Inc. | https://graphpad.com/scientific-software/prism/ |
| CTL-ImmuNoSpot® S6 Analyzer | Cellular Technology Limited | http://www.immunospot.com/ImmuNoSpot-analyzers |
| CytExpert | Beckman Coulter, Inc | https://www.beckman.com/coulter-flow-cytometers/cytolab/cytexpert |
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Rolf A. Brekken (rolf.brekken@utsouthwestern.edu).

Materials availability
This study did not generate new unique reagents.

Data and code availability

- Single-cell RNA-seq data have been deposited at GEO and are publicly available as of the date of publication. Accession numbers are listed in the key resources table.
- Microscopy data reported in this paper will be shared without restriction by the lead contact upon request.
- All original code has been deposited at Zenodo and is publicly available as of the date of publication. DOIs are listed in the key resources table.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell line and reagents
The KP and KPL cell lines were provided by Dr. Esra Akbay. The H2122 cell line was established by Drs. John Minna and Adi Gazdar at the NIH. A549 was obtained from ATCC. Lenti-X 293T cells were obtained from Takara (Cat# 632180). All cancer cell lines were grown in 5% FBS (ThermoFisher Scientific, Cat# 26140079) supplemented RPMI 1640 (Millipore Sigma, R8758). Cell lines were routinely tested using mycoplasma contamination kit (E-myc, Cat# 25233, Bulldog Bio) and cultured under 5% CO2 at 37 °C. Primary BMDCs and T cells were isolated from mice as described below and cultured in with complete RPMI 1640 medium supplemented with 20 ng/ml recombinant mouse GM-CSF (rmGM-CSF) in a 10-cm dish.
Humanized mice and human cord blood sample processing

Humanized mice were established as previously described.6 Briefly, 4-weeks-old NSG-SGM3 (Jackson Laboratories #013062) female recipient mice were treated with 100 cGy (X-ray irradiation with X-RAD 320 Irradiator) whole body irradiation within 24 h prior to hematopoietic stem cells (HSCs) transplantation. Human HSCs were isolated from human cord blood by Ficoll (Cytiva, Cat# 17544203) density gradient centrifugation, followed with positive immunomagnetic selection with anti-human CD34+ microbeads following the manufacturer’s protocol (STEMCELL Technologies, cat# 18780). For transplantation, 1 x 10^6 HSCs were intravenously injected into recipient mice. Irradiated mice were orally administrated Sulfadiazine/Trimethoprim (Aurora Pharmaceutical LLC, Cat# 302) water for 14 days.6,60 Twelve weeks after engraftment, humanized mice reconstituted with over 45% human CD45+ cells were used for tumor studies. Human cord blood samples were obtained from UT Southwestern (UTSW) Parkland Hospital in compliance to the regulation and the use approval of human cord blood (STU 112010-047) at UTSW medical center. Sterile blood was obtained at the time of cesarean section from de-identified human umbilical cords that are normally discarded. The procedure is approved through a protocol exempt from informed consent as approved by the institutional review board of UTSW and the Office for Human Research Protections (OHPR) supported by the U.S. Department of Health and Human Services. To maintain anonymity, links between the donor’s medical and social histories including fetal sex are not maintained.

Animal studies

Female C57BL/6J mice were purchased from the UT Southwestern breeding core or Taconic Biosciences. B6.129S7-Rag1tm1Mom/J (Rag1−/−), NOD.Cg-Pkdcsclid I2rgtm1Wjl Tg (CMV-IL3, CSF2, KITLG) 1Eav/MloySzJ (NSG-SGM3), B6.129S(C)-Batf3tm1Kmm/J (Batf3−/−), and C57BL/6J-Tg (TcraTcrb)1100Mjb/J (OT1 TCR transgenic mice) were purchased from Jackson Laboratory. All mice were housed by the UTSW Animal Resource Center at 68–79°F, 30–70% humidity, in individually ventilated cages, with no more than 5 mice per cage on 12 h on:off light:dark cycles. Mice were screened for and found free of MHV, Sendai virus, MPV, EDIM, MVM, PVM < TMEV-/GD-7, REO-3 virus, Mycoplasma pulmonis, pinworms, fur mites, LCMV, ECTRO, MAV, and K virus and had unrestricted access to RO chlorinated water and irradiated 2916 Teklab global diet (Envigo, Cat# 2916). Animal care and experiments were performed in complying with institutional and National Institutes of Health protocol and guidelines. This study has been approved by the Institutional Animal Care and Use Committee of the University of Texas Southwestern Medical Center (APN 2015–100921).

Clinical trial

Patients treated with bemcentinib and pembrolizumab combination therapy were enrolled in the BGBC008 clinical trial (BerGenBio ASA and Merck & Co., Inc., Kenilworth NJ, USA, NCT03184571). Information on demographics and characteristics of the three patients reported in this paper are given in Table 6. The clinical demographics and characteristics of the remaining patients enrolled onto the trial are not yet available because the trial is ongoing. The data presented here represent preliminary findings on 3 of the trial participants. Fine-needle aspirate biopsies of target lesions were acquired from patients at screening immediately prior to enrollment and preserved in formalin-fixed, paraffin-embedded (FFPE) tissue blocks. Patients were assessed for response according to RECIST 1.1 criteria at recurrent, scheduled scan intervals. The study was approved by all relevant institutions, including London Bridge Research Ethics Committee (UK), REC-South East (Norway), Drug Research Ethics Committee of the University Hospital Clinic of Barcelona (Spain), and MCW/FH Institutional Review Board #4, Medical College of Wisconsin (USA).

METHOD DETAILS

Cytotoxicity assays

For cell cytotoxicity analysis, 1000–2000 cells for corresponding cell lines were plated into each well of a 96-well plate. After 24 h, cells were treated with 4-fold serial dilutions of 8 different concentrations for 4 days. At the end time point of treatment, cell viabilities were determined using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS) (Promega, catalog# G3582) on a Molecular Devices SpectraMax 190 microplate reader under 450 nm wavelength. Dose-response curve was analyzed through GraphPad Prism.

OVA expressing cell line generation and characterization

The pCDH-EF1α-OVA plasmid (10 μg) was packaged with psPAX2 (5 μg) and pMD2.G (6 μg) into 2 million Lenti-X 293T cells (Takara, Cat# 632180) using FuGene6 (Promega, Cat# E2691) following the manufacturer’s protocol. Virus containing medium was removed after 12 h and viral supernatant was collected every day for 3 days and filtered through 0.45 μm filter. For virus infection, viral supernatant was mixed with polybrene (6 μg/ml, Santa Cruz, Cat# sc-134220) and incubated with cells overnight. Infected cells were then plated into 96-well plates to identify single clones. For OVA expression characterization, cells were stimulated with IFNγ (10 IU/ml) overnight then stained with OVA257-264 peptide bound to H-2Kb antibody (eBioscience, Cat# 17-5743-82). 2-3 OVA expressing single clones with similar behavioral and growth pattern with parental KPL were pooled as KPL-OVA.

In Vitro Co-culture of Bone Marrow Dendritic Cells (BMDCs) and T cells

To generate BMDCs, a single-cell suspension of bone marrow cells were collected from tibias and femurs of C57BL/6J or Axl−/− mice as previously described.61 Collected cells were cultured with complete RPMI 1640 medium supplemented with 20 ng/ml
recombinant mouse GM-CSF (mGM-CSF) in a 10-cm dish. On day 3 and 6, equal amount of fresh media containing 20 ng/ml mGM-CSF. The BMDCs were harvested from tissue culture suspension on day 7. For OVA specific CD8+ T cells, the spleen and lymph nodes of OT1 transgenic mice were isolated with a negative CD8+ T cell isolation kit (STEMCELL Technologies, Cat# 19853) following the manufacturer’s instructions. For co-culture, 2 × 10^6 BMDCs were mixed with 2 × 10^6 CD8+ T cells in the presence of 100 µg/ml OVA protein per well in a 96-well U-bottom plate. BGB324 at 40 nM was added. For in vitro IFNα receptor blockade, 10 µg of anti-mouse IFNAR-1 antibody (BioXCell, Cat# BE0241) or corresponding IgG (BioXCell, Cat# BE0083) was added. For in vitro IFNα stimulation, 0.5 ng/ml of recombinant IFNα was added. After 48hr, all the cells were collected for analysis by flow cytometry.

**Immunoblots**

For LKB1 protein detection, KP and KPL cells were cultured in vitro. Protein lysates were collected by washing cells with ice-cold PBS then incubated with a modified RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 1% IGEPAL CA-630, 1% sodium deoxycholate, 2 mM MgCl2, pH 8) with 1 unit/µl benzonase (MilliporeSigma, Cat# E1014), protease inhibitors (MilliporeSigma, Cat# P8340) and phosphatase inhibitors (MilliporeSigma, Cat# 4906845001) on ice for 15 min. Lysed cells were scraped and protein lysates were harvested. The concentration of total protein was quantified with Bradford Assay (Bio-Rad, Cat# 5000006) according to BSA standard (ThermoFisher Scientific, Cat# 23209). For each sample, 25 µg protein was mixed with loading dye and separated on a NuPAGE 4-20% TGX gel (Bio-Rad, Cat# 5671095) at 150V. Samples were transferred with the Trans-Blot Turbo RTA Mini Nitrocellulose transfer kit (Bio-Rad, Cat# 1704270) on a Trans-Blot Turbo Transfer System (Bio-Rad, Cat# 1704150) following manufacturer’s recommended protocols. The membrane was blocked with 5% milk (Bio-Rad, Cat# 1706404XTU) dissolved in 0.1% in PBST. Membrane was probed with primary antibodies: LKB1 (1:1000, Cell Signaling Technology, Cat# 3047) and GAPDH (1:2500, Cell Signaling Technology, Cat# 5174), blots were incubated at 4°C overnight. After washing with 0.1% PBST, the membranes were with secondary antibody (1:2000, Cell Signaling Technology, Cat# 7074), washed and imaged with ECL substrate (Bio-Rad, Cat# 1705062), and visualized through a LiCor Odyssey Fc imaging system.

**Tumor growth and treatment**

For subcutaneous allografts, 1 × 10^6 cells in 100 µl phosphate buffered saline (PBS) were injected into right dorsal flanks of 6-8 wks old mice. For xenografts growing in humanized mice, 1.5 × 10^6 cells in 100 µl phosphate buffered saline (PBS) were injected into right dorsal flanks. Tumor bearing mice were randomly grouped into treatment groups when tumor volume was 100-150 mm^3. For each treatment group, 5 mice were assigned. 10 mg/kg PD-1 (BioXCell, Cat# BE0146) treatment was given intraperitoneally on day 0, day 4 and day 7 after treatment. Control animals were treated with 10 mg/kg rat IgG2a isotype control (BioXCell, Cat# BE0089). BGB324 (50 mg/kg) was given through oral gavage twice daily. For tumor growth measurement, mice were treated for 3 weeks. For tumor microenvironment analysis, mice were treated for 7 days, harvested tumors from control and treatment groups were within 20% in size for TME analysis. For intratumoral IFNα receptor blocking, 50 µg IFNAR blocking (BioXCell, Cat# BE0241) antibody or control IgG (BioXCell, Cat# BE0083) were injected intratumorally 1 day before BGB324 + anti-PD-1 treatment started. IFNAR inhibition antibody was injected every other day. For Clophosome liposome depletion (FormuMax Scientific, Cat# F70101C-A), the amount of liposome recommended by corresponding COA was injected intraperitoneally into mice 1 day before therapy (BGB324 + anti-PD-1) treatment. After 5 days, a second liposome injection was performed. For recombinant IFNα, 200 ng of IFNα or PBS was injected intraperitoneally 14 days after tumor inoculation. Tumor volumes were measured by length (a), width (b) and height (h) in every 3 days and calculated as tumor volume = abh.

**IFN-γ enzyme-linked immunosorbent spot assay (ELISPOT)**

KPL-OVA (1 × 10^6) cells were injected subcutaneously on the right flank of 6-8 weeks old C57BL/6J mice purchased from Taconic Biosciences. Seven days after treatment started, tumors were harvested and digested into single cells. For each well of a 96-well plate, tumor infiltrated lymphocytes (TILs) were isolated from 3 × 10^6 digested single cells by biotin labeling (BioLegend, Cat# 101304) followed by negative immunomagnetic selection (STEMCELL Technologies, Cat# 19860). Isolated TILs were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. For antigen specific CD8+ T cell stimulation, 1 µg/ml of SIINFEKL peptide (OVA257-264) or control RAHYNIVTF (E7) peptide were added. After 48 hr of incubation, IFN-γ production was determined with an IFN-γ ELISPOT assay kit according to the manufacturer’s protocol (BD Biosciences, Cat# 551083). The visualized spots were enumerated with the CTL-ImmuNoSpot® S6 Analyzer (Cellular Technology Limited) and normalized based on digested tumor cell counts.

**Enzyme-Linked Immunosorbent Assay (ELISA)**

Co-culture of BMDCs with irradiated tumor cells to detect type I IFN was performed as previously described. BMDCs (2 × 10^6) were co-cultured with 40g irradiated KPL cells (2 × 10^6), with or without BGB324 treatment (40 nM). After 24 h, cell supernatant was collected for analysis. The concentration of IFNαβ was measured by VeriKine-HS Mouse IFN Beta Serum ELISA kit (PBL Assay Science, Cat# 42410), or VerKine Human IFN Beta ELISA kit (PBL Assay Science, Cat# 414101) in accordance with the manufacturer’s instructions. Finally, the plates were visualized by adding 100 µL of TMB solution and read at 450 nm using the SPECTROstarNano (BMG LABTECH).
Single cell preparation for flow sorting and flow cytometry

Tumor tissues were excised and digested with 2 mg/mL Collagenase A (Sigma, Cat# SCR136) and 1 mg/ml DNase I (Roche, Cat#1284932001) under 37 °C, 150 rpm shaking speed for 45 min. Digested materials then were transferred to a 70 μm cell strainer to remove clumped cells. Digested cells were washed twice with FACSs buffer and ready for downstream analysis.

Library preparation and construction for scRNA-seq and scTCR-seq

KP (n = 10) and KPL (n = 10) allografts were harvested 14 days after subcutaneous implantation (average tumor size ~200 mm³). For each sample, individual tumors harvested from different mice were pooled with live CD45+ CD3⁺ CD45⁺ CD3⁺ cells sorted and mixed back as 1:1 ratio. Single cell libraries and TCR libraries were generated with Chromium Single Cell V(D)J Reagent Kit (10x Genomics, PN-10000006, PN-10000009, PN-1000071) following per manufacturer’s instruction. Pooled control group tumors from KPL tumors were also used to compare with KP tumors.

Flow cytometry analysis

Total number of digested cells for each tumor sample was counted, and a single cell suspension of 1.5 million of cells was used to perform analysis. Samples were incubated with anti-FcγIII/II receptor (clone 2.4G2) for 15 min at 4°C to block potential non-specific binding of conjugated antibodies. Indicated antibodies were incubated with digested tumor samples for 30 min at 4°C. Fixable viability Dye eFluor 506 (eBioscience, Cat# 65-0866-18) was used to exclude the dead cells. Ki67 and TCF1 were stained intracellularly using True-Nuclear transcription factor buffer set (BioLegend, Cat# 424401) following the manufacturer’s instructions. Data were collected on CytoFLEX flow cytometer (Beckman Coulter, Inc) and analyzed by using FlowJo (Tree Star Inc., Ashland, OR) software.

Hematoxylin and Eosin (H&E) staining

Formalin paraffin embedded slides (5 μm) were deparaffinized with xylene, ethanol, and deionized water. Slides were then stained with hematoxylin (Fisher Chemical, Cat# SH26500D) and washed/destained with acid ethanol. Eosin (Poly Scientific, Cat# s176) was then applied to slides and then washed with 95% ethanol. Stained slides were dehydrated with ethanol and xylene.

Multiplex immunohistochemistry (IHC)

Multiplex immunohistochemistry (IHC) was performed as previously described.62 Briefly, slides were warmed in a 60 °C oven for 10 min followed by deparaffinization and rehydration. Before antigen retrieval, slides were fixed in 10% neutral buffered formalin for 30 min followed by a PBS wash. Antigen retrieval was performed in antigen retrieval buffer (10 mM Tris-HCl, 1 mM EDTA with 10% glycerol [pH 9]) at 110 °C for 17 min (4–5×). Slides were cooled down to room temperature and washed once with PBS. Tissue sections were blocked with 2.5% goat serum (Vector Laboratories, S-1012) for 30 min followed by incubation with primary antibody (CD8, 1:2000; Cell Signaling, 98941) overnight at 4°C. Slides were washed three times for 5 min in PBST (0.05% Tween 20 and 2 mM EDTA) and incubated with HRP conjugated secondary anti-rabbit Antibody (ImmPRESS; Vector Laboratories, MP-7401) for 30 min on a shaker. Slides were then washed three times for 5 min in PBST. For developing the fluorescence signal, TSA detection system (PerkinElmer) was used. We used Opal 520 to stain for CD8. Multiplex staining was performed by stripping the previous antibody in 10 mM citrate buffer (pH 6.2) plus 10% glycerol at 110 °C for 2 min before blocking and probing with the next primary Ab: TCF1/7 (1:1000, Cell Signaling). Following similar steps from the first round of staining, slides were developed with Opal570 to stain for TCF1/7. Slides were counter-stained with DAPI and then cover-slipped using Pro-Long Gold mount (No. P36931; Life Technologies). Slides were scanned at 20X using the Zeiss Axiocan.Z1 (Whole Brain Microscopy Facility, UT Southwestern). DAPI, AF488 (for Opal520) and AF555 (for Opal570) channels were used to acquire images.

Tissue microarrays immunohistochemistry staining

Tissue microarrays (TMAs) were generated with resected Non-small cell lung carcinoma tumor samples (TMA3). IHC staining was performed on 4-μm thickness TMAs sections in a Leica Bond RX automated strainer (Leica Biosystems). Antigen retrieval was performed with Bond ER Solution #1 (Leica Biosystems) equivalent to citrate buffer, pH 9.0 for 20 min at 100 °C. The sections were incubated with anti-AXL antibody (rabbit monoclonal, Cell Signaling clone C89E7); 1:300 dilution (1 μg/ml). The antibody was detected using Bond Polymer Refine Detection kit (Leica Biosystems) with diaminobenzidine (DAB) as chromogen. All the slides were counterstained with hematoxylin, dehydrated, and cover slipped. Tonsil and normal colon sections were used as external positive controls. Each case was analyzed using standard microscopy by two pathologists (LS, SH) in immune cells and reported as percentage of the tumor area occupied with immune cell with cytoplasmic and/or membrane expression.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis

All data were processed and analyzed through GraphPad Prism statistical software (version 9.0.0, GraphPad Software Inc.) and shown as mean ± SD. One-way ANOVA with Tukey’s multiple comparison test was used to compare tumor growth and MFIs with more than 2 treatment groups, and unpaired two-tailed t tests was used to analyze the other data. Chi-square test was used for
IHC image quantification analysis. A value of \( p < 0.05 \) was considered statistically significant (*\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \) and ****\( p < 0.0001 \)).

**Flow cytometry cell number normalization**
The absolute cell number of designated cell populations were calculated based on the percentage of infiltrated cells, normalized with absolute cell number of harvested tumor and measured tumor size.

**scRNA-seq and scTCR-seq data processing**
Sequenced scRNA-seq samples were processed through Cellranger pipelines (v3.1.0). Cellranger count was used to align reads to mouse reference genome (mm10, 2020-A, from 10x Genomics) and generate single cell feature counts for single library. For scTCR-seq data, TCR reads were aligned to reference genome and TCR annotation was performed using the 10x cellranger vdj pipeline with provided reference (cellranger-vgdj-GRCm38-als-ensembl-4.0.0). Overall, 94% of T cells in scRNA-seq data were assigned a TCR and more than 70% had at least one full-length productive CDR3 for TRB. Cellranger aggr were applied next to aggregate each sample library for grouped analysis with same effective sequencing depth. Seurat (3.2.1) package was used for multiple library data integration and downstream analysis including singlet filtration, dimensional reduction, data scaling, clustering and markers identification.

**Annotation of cell clusters and data visualization**
To identify the cell clusters, we annotated the cell cluster identities based on (1) well-studied marker genes of different immune cell types were in the top rank of differential expressed genes and assign the identity to the most likely cell populations; (2) unbiased cell population identification package singleR (v1.3.8). For visualization, we applied the uniform manifold approximation and projection (UMAP) to visualize cell clusters. For CD8+ T cells sub-clustering, we split the CD3+ T cells according to the mutually exclusive expression of CD4 (CD4> 1 and CD8A< 1) and CD8A (CD4<1 and CD8A>1) genes based on their normalized expression. CD8+ T cells were then sub-clustered and annotated based on their highly enriched genes with well-known markers.

**Differential expression analysis**
CD8a expressing T cells were subset and analyzed for differential expressed gene among KP and KPL samples using Seurat package (3.2.1). Then differential expressed genes were ranked based on log Fc value, with p value >0.01 highlighted in grey, and p value <0.01 highlighted in red. Then the graph was plotted using ggplot 2 package.

**Characterization of sample enrichment and state transition of T cell clusters**
To measure the enrichment of specific T cell clusters in each sample induced by different treatment, we calculated the ratio of observed to expected cell number for each T cell cluster. Chisq-squared test was applied to test whether the distribution of T cell clusters across different samples was significantly deviates from random expectations. The extent of deviation for each combination of T cell cluster and sample is quantified by the Ro/e value:

\[
R_{o/e} = \frac{N_o}{N_e}
\]

where \( N_o \) is the observed number cell for a given sample and cluster combination, while the \( N_e \) is the expected number obtained from Chi-square test. Theoretically, \( R_{o/e} > 1 \) suggests that cells identified in the given cluster shows higher frequency than random expectations for the analyzed sample, and vice versa. The normalization and scaling of the shared clonotypes between CD8 T cell clusters was performed and analyzed based on previous publication. The shared clone scores were also scaled with a constant of 10,000.

**RNA velocity analysis**
To predict the future status and direction of each cells transitioning, RNA velocity analysis was performed. Un-spliced mRNAs were generated as a loom file for each individual sample output from Cell Ranger and RNA velocity was calculated based on velocyto (v0.17.17, Linux R package). Generated loom files were then merged and projected to UMAP coordinates of single cells.

**ADDITIONAL RESOURCES**
This paper reports preliminary data from a clinical trial (NCT03184571).